Beyond Celiac Launches First Investment Program for Celiac Disease Therapeutics
PHILADELPHIA, Feb. 15, 2024 /PRNewswire/ -- Beyond Celiac, the leading catalyst for a cure for celiac disease, today announces the creation of Beyond Celiac Investments (BCI), an investment program to accelerate the development of treatments and a cure for celiac disease by leveraging the speed and scale of venture capital and capital markets. BCI launches with an initial funding of $2 million and additional capital will be raised through donations.
- PHILADELPHIA, Feb. 15, 2024 /PRNewswire/ -- Beyond Celiac , the leading catalyst for a cure for celiac disease, today announces the creation of Beyond Celiac Investments (BCI), an investment program to accelerate the development of treatments and a cure for celiac disease by leveraging the speed and scale of venture capital and capital markets.
- Our scientific and business expertise in selecting and supporting these treatments reduces risk, cost and time to market for potential celiac disease treatments," she adds.
- Beyond Celiac is the nation's top recruiter for celiac disease clinical trials and works with pharmaceutical companies to ensure that trials are designed with the patient perspective in mind.
- Beyond Celiac is the largest 501(c)3 celiac disease research grant funder, including five research grants totaling $1.6 million in 2023.